MLHP $$$$ is Flying $$$$$$$$$$$$$$$

[JohnJohnson]

MLHP $$$$ is Flying $$$$$$$$$$$$$$$

[JohnJohnson]

[b][url]http://translate.google.de/translate?hl=de&sl=hr&tl=de&u=htt

[JohnJohnson]

MLHP is going to Multiple Pennyland $$$$$$$$$$$

A fully integrated biopharmaceutical company that shareholders value and there is hope for the global fight against devastating diseases that develop through the development of innovative quality products that improve quality of life and promoting health.


Our commitment is hope for humanity


-------------------------------------------------- ------------------------------

Millennia Hope is to the patients and physicians for our therapy is a significant improvement over existing drugs is achieved.

Millennia Hope is to provide our shareholders value through the delivery of a fair and equitable return on investment.

Millennia Hope is committed to develop new drugs in the field of malaria and AIDS.

Millennia Hope is to act interested parties to adopt socially responsible way by requiring broad access to effective treatment.

Our commitment to our employees and partners is to help them achieve their goals, how they work and relate to our business objectives.
Research & Development Research & Development

Since its inception the company has established excellent contacts between physicians, clinical researchers and basic scientists acquired the patent rights for an exciting new anti-malaria funds, moved to acquire control of production facilities for MMH

[JohnJohnson]

Posted by: STOCK_MOMO Date: Friday, October 30, 2009 1:41:51 PM
In reply to: niter who wrote msg# 410 Post # of 424

Looks thin to a penny. Be nice to see news Monday morning. These bios close at .00 and open at dollars

[JohnJohnson]

Millenia (MLHP)also can be helpful resource for swine flu vaccine
The H1N1 pandemic, otherwise known as Swine flu derived from pigs has spread to 159 countries and territories around the world, with a cumulative number of 146 609 confirmed cases and 1 096 confirmed deaths

Read more:
Millenia Hope Inc., a Bio Pharma (OTC Bulletin Board: MLHP; Frankfurt: MLF), announced today that the prestigious Canadian Law Firm, Heenan Blaikie, with the support of one of its senior partners, the Rt. Honorable Jean Chretien, former Prime Minister of Canada for 10 years and a great advocate for the people of Africa, has pledged its resources to help alleviate the human suffering and devastation caused by malaria in Africa. Millenia Hope, a Montreal, Canada based U.S. Biopharma, has dedicated its resources for the past nine years to developing its anti-malarial drug, Malarex/MMH 18.
Heenan Blaikie and Mr. Chretien have committed themselves to fight debilitating infectious diseases in Africa, with an initial focus on malaria. They are appealing to the supporters of this noble cause to join them in fighting these devastating diseases. In an effort to initiate this crusade against malaria, they have chosen to join hands with Millenia Hope Inc. Heenan Blaikie applauds the passion and commitment of Millenia's tenacious efforts to develop a global solution for the Malaria disease. Mr. Jacques Bouchard Jr., spearheading Heenan Blaikie's efforts in this regard, has been instrumental in forging this unique humanitarian alliance between Heenan Blaikie, and Millenia Hope Inc., to fight malaria in Africa.

Leonard Stella, Chairman and CEO of Millenia Hope, stated, "Heenan Blaikie, represented in this effort by Former Prime Minister Chretien, has pledged itself as Canadian goodwill Ambassadors to do their utmost to help Africa. We hope and pray that their fiery passion and our total commitment to alleviate the suffering caused by malaria will be dawn of a new era for the people of Africa."

ABOUT MILLENIA HOPE:

Millenia Hope develops innovative treatments and products that enhance the quality of life, has put in place programs to fight major infectious diseases, and promote healthier lives. Our team is committed to research and development to deliver on global medical needs and to bring hope through healthcare solutions.

ABOUT HEENAN BLAIKIE:

Heenan Blaikie has become one of the leading law firms in Canada. The firm is over 400 lawyers strong and has been involved in commercial transactions and advisory projects all over the world, more specifically in many African countries.

Heenan Blaikie has within its ranks a number of prominent individuals who have made their mark on the international stage, including the Rt. Honorable Jean Chretien, P.C., Q.C., former Prime Minister of Canada, Pierre-Marc Johnson, Former Premier of the Province of Quebec as well as the Honorable Donald J. Johnston, the Former Secretary-General of the OECD.

SAFE HARBOR STATEMENTS:

Certain statements made in the release may contain language describing the plans, goals, strategies, intentions, forecasts, and expectations of Millenia Hope/Millenia Hope Biopharma that may be referred to as "forward-looking statements." Several important factors could cause actual results to differ materially from those in such forward-looking statements and Millenia Hope could encounter unanticipated obstacles and delays in developing products, services and markets.

Millenia Hope Inc.

[JohnJohnson]

MLHP.The H1N1 pandemic.OTC Bulletin Board: MLHP; Frankfurt: MLF), I'm so excited about that.Not to many peeps recognized yet about this possibility.If this news will spread around ,MLHP will fly above stratosphere.IMO Good luck from SA

[JohnJohnson]

Posted by: Kommandorobotts Date: Sunday, November 01, 2009 12:09:29 PM
In reply to: None Post # of 452

So.When we are breaking 0,005 - We are easyly at Pennyland 0,02+ - So, when the pr come bevore opening Us exchange, Oh my Gott we are definetly at US Dollars, The pps will explode explode and explode - Big PPS. Risings Ups $$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$ $$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$ $$$$$$$$$$$$$$$$$$
$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$

Congratulations to All $$$$$$$$$

[JohnJohnson]

WILMINGTON, Del., -- Millenia Hope Inc., a biopharma corporation ( OTC Bulletin Board = MLHP ) , has acquired a patent (pending) on AIDS that specifically describes compounds that inhibit HIV-1 RNase_H. The viral RNase_H has been shown to be essential for HIV replication. There are no inhibitors of HIV-1 RNase_H in clinical development at this time. In fact, very few such inhibitors have even been identified for this target. Successful development of this drug will play an important role in the treatment of AIDS patients who have become resistant to current therapy. Projected revenue for an orally bio-available (first in class) drug for AIDS is estimated at $350-$500 million US. The current market of AIDS drugs is $6 billion US, estimated to reach $10 billion by 2010. RNase_H preliminary results were presented at a major AIDS conference in Boston in 2005 to great interest from several large pharmaceutical and biotech companies.

Furthermore, Leonard Stella, Chairman & CEO of Millenia Hope is pleased to announce that its subsidiary's (MH-B) acquisition of the operations and technological expertise of the former Avance Pharma has been seamlessly implemented. MH-B is headed by a group of scientists, renowned in their fields of expertise:

Jean Archambault, Ph.D., MBA

President & COO-Director of Millenia Hope BioPharma (MH-B)

Founder of Avance Pharma, Dr. Archambault has been instrumental in developing and implementing the Company's unique drug discovery technology platform and creating the world's largest library of plant cell cultures. Prior to founding Avance Pharma, Dr. Archambault was a professor and department head of Chemical Engineering at the University of Quebec. Previously, Dr. Archambault headed the Cell Culture Group at the National Research Council of Canada's Biotechnology Research Institute where he developed and directed all mammalian, insect and plant cell bioengineering R&D activities.

Bahige Baroudy, Ph.D.

President & Chief Science Officer-Director of Millenia Hope Inc.

Chief Science Officer-Director of Millenia Hope BioPharma (MH-B)

Dr. Baroudy has multi-disciplinary expertise in basic research, infectious disease drug discovery and virology. Prior to joining Avance Pharma, Dr. Baroudy was a Group Director at Schering-Plough where he spearheaded the development of CCR5 antagonists that are currently in clinical trials as HIV entry inhibitors and earned a place on "The Scientific American 50" list as the top Research Leader in 2003 in this category. He was also the Director, Division of Molecular Virology at the James N. Gamble Institute of Medical Research, where he established research programs in viral hepatitis and liver diseases, HIV/AIDS and vaccinia virus expression and pathogenesis. Dr. Baroudy has also worked at the NIH in several disciplines.

Robert Williams, Ph.D.

Chief Development Officer-Director of Millenia Hope BioPharma (MH-B)

Dr. Williams, one of the co-founders of Avance Pharma, has been instrumental in the development of Avance Pharma's cell culture facility and in all aspects of the generation of Avance Pharma's proprietary library of purified fractions. His extensive cell culture expertise has now turned towards the generation of cell lines from selected plant species for the industrial production of biochemicals of interest to pharmaceutical and cosmetic companies. He has published numerous papers on all aspects of cell culture metabolism and metabolite production.

Dany Aubry, P.eng. M.Sc.A.

Chief Technical Officer-Director of Millenia Hope BioPharma (MH-B)

Mr. Aubry, with 13 years of experience in developing plant cell culture bioprocesses, was the Director of Operations at Avance Pharma from 2002 to 2005, overseeing all operational aspects of its Phytomics Technologies, including the R&D programs, cell line generation, biosynthesis and purification of phytochemicals, scale-up of bioprocesses, setting up of laboratory facilities, as well as control of the supply chain for drug discovery activities. His expertise in plant cell cultures covers all aspects of bioprocess development & control as well as bioreactor design.

In other corporate news, Ms. Carole Robert, the former V.P. of Government Affairs and Sales Development, left Millenia's employment and her portfolio has been divided amongst several officers. Mr. Thomas Bourne, Corporate secretary, tendered his resignation and his duties are being carried out by Mr. Jacky Quan, Executive V.P. and Treasurer.

About Millenia Hope:

Millenia Hope develops innovative treatments and quality products that will increase the quality of life, provide tools in the fight against diseases, and promote healthier lives. Our team is committed to research and development to deliver on global medical needs and to bring hope through healthcare solutions.

About MH-B:

MH-B is one of the world's leading bio-research firms in Phytomic Technology, the commercialization of plant cell cultures. MH-B (formerly Avance Pharma) has spent over $30 million in creating its unique technology, including the world's largest collection of highly purified phyto-chemical fractions to be utilized in the pharmaceutical, cosmetic and nutraceutical industry and is commencing the initial commercialization of several projects, with leading multi-national corporations.

Safe Harbor Statement:

Certain statements made in this release may contain language describing the plans, goals, strategies, intentions, forecasts and expectations of Millenia Hope that may be referred to as "forward-looking statements." Several important factors could cause actual results to differ materially from those in such forward-looking statements, and Millenia Hope could encounter unanticipated obstacles and delays in developing products, services and markets.


For more information please contact:

Mr. Hugo Valente, CFO
Tel.: 514-846-5757




This release was issued through eReleases(TM). For more information, visit .

[JohnJohnson]

Dr. Soriba Cisse, Chief Scientific Officer